ADAM9 and thyroid gland carcinoma: To test whether miR-182-5p/ADAM9 axis was involved in RUNDC3A-AS1 promoted thyroid cancer progression, miR-182-5p inhibitors and ADAM9 shRNAs were transfected into K1 cells in the presence with RUNDC3A-AS1 shRNAs.